Prosecution Insights
Last updated: November 20, 2026
Application No. 18/035,502

NOVEL VHL SMALL MOLECULE PROBES

Non-Final OA §102§112
Filed
May 04, 2023
Priority
Nov 09, 2020 — provisional 63/111,407 +1 more
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
St. Jude Children's Research Hospital Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
775 granted / 1055 resolved
+13.5% vs TC avg
Strong +23% interview lift
Without
With
+23.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
54 currently pending
Career history
1111
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
18.7%
-21.3% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
33.0%
-7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1055 resolved cases

Office Action

§102 §112
DETAILED ACTION Claims 1, 2, 4, 5, 7-10, 17-19, 24, 26, 28, 30, 32, 33, 35, 36, and 53 are currently pending in the instant application. Claims 1, 5, 7-10, 17-19, 24, 26, and 28 are rejected. Claims 2, 4, 30, 36, and 53 are withdrawn from consideration as being for non-elected subject matter. Claims 32, 33, and 35 are objected. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I and the species PNG media_image1.png 188 500 media_image1.png Greyscale in the reply filed on 2 March 2026 is acknowledged. According to MPEP 803.02, the examiner has determined whether the elected species is allowable. Applicants’ elected species appears allowable. Therefore, the search and examination has been extended to the compounds of claims 32, 33, and 35 which appear allowable, and further to the compounds: PNG media_image2.png 232 668 media_image2.png Greyscale and PNG media_image3.png 182 416 media_image3.png Greyscale : which are not allowable. Claims 1, 5, 7-10, 17-19, 24, 26, 28, 32, 33, and 35 have been examined to the extent that they are readable on the elected embodiment, the elected species and the above mentioned compounds. In regards to claim 30, while applicant states that claim 30 reads on the elected species, claim 30 is considered withdrawn as the elected species has the position equivalent to Q on the formula as -C(R10a)(R10b)C(O)-, however, the compound in claim 30 does not have the position equivalent to Q as -C(R10a)(R10b)C(O)-, but has CH2. Claim Objections Claims 32, 33, and 35 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 5, 7-10, 17-19, 24, 26, and 28 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Specifically, claim 1 defines R1 as “a residue of a fluorophore, a residue of biotin, or a residue of a biotin derivative”, defines L as “a linker” and defines R2 as “a residue of a pVHL ligand.” The term “residue” is defined on page 17 of the specification paragraph [0056] which provides that a residue of a chemical species refers to the moiety that is the resulting product of the chemical species in a particular reaction scheme or subsequent formulation or chemical product, regardless of whether the moiety is actually obtained from the chemical species. Additionally, “derivative” is defined on page 16 paragraph [0054] as a compound having a structure derived from the structure of a parent compound and whose structure is sufficiently similar to those disclosed herein and based upon that similarity would be expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compounds including salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound. Besides these definitions of “residue” and “derivative” there is no written description for how to make or use any “residue of a fluorophore, a residue of biotin, a residue of a biotin derivative, or a residue of a pVHL ligand” as there is no written description other than the definitions on pages 16 and 17 on how to determine a particular reaction scheme to produce a residue, or how to prepare a subsequent formulation or chemical product and how far from the original starting product, the residue can be in regards to structure, i.e. what is required in the moiety that is the resulting product, especially since according to page 17, the residue does not even need to be prepared from the chemical species. There is no written description on what other reactants could start the reaction scheme to produce a residue. The only written description provided are for specific defined formula such as page 35, which provides a specific residue of a pVHL ligand wherein the residue of the pVHL ligand HAS the structure PNG media_image4.png 228 252 media_image4.png Greyscale There is no other description for other “residues of a pVHL ligand” or how to make any other residues or use other residues. Linker is defined on page 40 and the only examples are C2-C15 alkyl and –(CH2CH2O)n. There is no written description for how to prepare or use any other linker. Page 41 provides specific defined formula for a residue of a fluorophore, wherein the residue of a fluorophore HAS the structures in paragraph [00152]. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 recites the limitation “wherein the BODIPY fluorophore is” in reference to the compound of claim 5. There is insufficient antecedent basis for this limitation in the claim as claim 5 provides that R1 is a residue of a fluorophore and does not provide wherein the fluorophore is a BODIPY fluorophore. It is suggested that claim 8 be amended to depend from claim 7 which does contain a BODIPY fluorophore. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 5, 7-10, 17-19, 24, 26, and 28 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by: PNG media_image5.png 48 526 media_image5.png Greyscale published online October 18, 2020. Lin, Wenwei, et al. provides the compound (19) on page 2564: PNG media_image3.png 182 416 media_image3.png Greyscale The compound (19) corresponds to instant claim 1 wherein L is a linker, R1 is a residue of a fluorophore, and R2 is a von Hippel-Lindau protein ligand. The compound corresponds to claim 5 wherein R1 is a residue of fluorophore, specifically -NH2. Please note the definition of a residue on page 17 of the specification paragraph [0056] which provides that a residue of a chemical species refers to the moiety that is the resulting product of the chemical species in a particular reaction scheme or subsequent formulation or chemical product, regardless of whether the moiety is actually obtained from the chemical species. Therefore, a residue of a fluorophore can be any moiety that can be a resulting product of the fluorophore in any reaction scheme, or a subsequent formulation or chemical product, regardless of whether the moiety is actually obtained from the chemical species. Therefore, -NH2 of the compound (19) is considered a residue of a fluorophore. The compound corresponds to claim 7 wherein R1 is a residue a 4,4-difluoro-4-bora-3a,4a-diaza-s-inndacene (BODIPY) fluorophore, specifically -NH2. The compound corresponds to claim 8 wherein R1 is a residue of the specific BODIPY fluorophore listed, specifically -NH2. The compound corresponds to claim 9 wherein R1 is a residue of the BODIPY fluorophore species shown, specifically -NH2. The compound corresponds to claim 10 wherein L is selected from –(CH2CH2O)n wherein n is 4. The compound corresponds to claim 17 wherein the residue of the pVHL ligand has a structure represented by a formula: PNG media_image6.png 200 244 media_image6.png Greyscale wherein R6 is hydrogen; R5 is hydrogen; R4 is tert-butyl; R3 is hydrogen; m is 1; and Q is -C(R10a)(R10b)C(O)-; R10a and R10b are each hydrogen. The compound corresponds to claim 18 wherein each of R3, R5, and R6 is hydrogen. The compound corresponds to claim 19 wherein R4 is tert-butyl. The compound corresponds to claim 24 wherein the residue of the pVHL ligand has a structure represented by a formula: PNG media_image7.png 192 254 media_image7.png Greyscale . The compound corresponds to claim 26 wherein the residue of the pVHL ligand has a structure: PNG media_image8.png 228 210 media_image8.png Greyscale . The compound corresponds to claim 28 wherein the compound has a structure represented by formula: PNG media_image9.png 214 250 media_image9.png Greyscale wherein m is 1; Q is -C(R10a)(R10b)C(O)-; each R10a and R10b is hydrogen; R1 is a 4,4-difluoro-4-bora-3a,4a-diaza-s-inndacene (BODIPY) fluorophore; R3 is hydrogen; R4 is C1-4 alkyl, specifically tert-butyl; R5 and R6 are each hydrogen; and L is a linker. Claim(s) 1, 5, 7-10, 17, 18, 19, 24, 26, and 28 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2019/084026. WO 2019/084026 discloses the compound NanoBRETTM Tracer-PEG2-590 on page 465: PNG media_image2.png 232 668 media_image2.png Greyscale along with the parental unlabeled VHL antagonist: PNG media_image10.png 274 476 media_image10.png Greyscale . The compound NanoBRETTM Tracer-PEG2-590 corresponds to instant claim 1 wherein L is a linker, R1 is a residue of a fluorophore, and R2 is a von Hippel-Lindau protein ligand. The compound corresponds to claim 5 wherein R1 is a residue of fluorophore. The compound corresponds to claim 7 wherein the fluorophore is a 4,4-difluoro-4-bora-3a,4a-diaza-s-inndacene (BODIPY) fluorophore. In regards to claims 8 and 9, please note the definition of a residue on page 17 of the specification paragraph [0056] which provides that a residue of a chemical species refers to the moiety that is the resulting product of the chemical species in a particular reaction scheme or subsequent formulation or chemical product, regardless of whether the moiety is actually obtained from the chemical species. Therefore, a residue of a fluorophore can be any moiety that can be a resulting product of the fluorophore in any reaction scheme, or a subsequent formulation or chemical product, regardless of whether the moiety is actually obtained from the chemical species. Therefore, PNG media_image11.png 184 200 media_image11.png Greyscale is considered a residue of a fluorophore. The compound corresponds to claim 8 wherein R1 is a residue of the specific BODIPY fluorophore listed, specifically the residue is PNG media_image11.png 184 200 media_image11.png Greyscale as the listed BODIPY fluorophore can produce the residue PNG media_image11.png 184 200 media_image11.png Greyscale in a reaction scheme or subsequent formulation, regardless of whether the moiety is actually obtained from the chemical species. The compound corresponds to claim 9 wherein R1 is a residue of the BODIPY fluorophore species shown, specifically the residue is PNG media_image11.png 184 200 media_image11.png Greyscale .. The compound corresponds to claim 10 wherein L is selected from –(CH2CH2O)n wherein n is 2. The compound corresponds to claim 17 wherein the residue of the pVHL ligand has a structure represented by a formula: PNG media_image6.png 200 244 media_image6.png Greyscale wherein R6 is hydrogen; R5 is hydrogen; R4 is tert-butyl; R3 is hydrogen; m is 1; and Q is -C(R10a)(R10b)C(O)-; R10a and R10b are each hydrogen. The compound corresponds to claim 18 wherein each of R3, R5, and R6 is hydrogen. The compound corresponds to claim 19 wherein R4 is tert-butyl. The compound corresponds to claim 24 wherein the residue of the pVHL ligand has a structure represented by a formula: PNG media_image7.png 192 254 media_image7.png Greyscale . The compound corresponds to claim 26 wherein the residue of the pVHL ligand has a structure: PNG media_image8.png 228 210 media_image8.png Greyscale . The compound corresponds to claim 28 wherein the compound has a structure represented by formula: PNG media_image9.png 214 250 media_image9.png Greyscale wherein m is 1; Q is -C(R10a)(R10b)C(O)-; each R10a and R10b is hydrogen; R1 is a 4,4-difluoro-4-bora-3a,4a-diaza-s-inndacene (BODIPY) fluorophore; R3 is hydrogen; R4 is C1-4 alkyl, specifically tert-butyl; R5 and R6 are each hydrogen; and L is a linker. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 14 May 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

May 04, 2023
Application Filed
May 15, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799154
PROCESS FOR PREPARING HIGH PURITY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF
5y 2m to grant Granted Nov 17, 2026
Patent 12799155
Process for the preparation of B-[(7alpha,17beta)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl) sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid and intermediates of said process
3y 0m to grant Granted Nov 17, 2026
Patent 12799134
N-MACROCYCLIC AMIDE COMPOUNDS, PREPARATION METHODS THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS
3y 5m to grant Granted Nov 17, 2026
Patent 12799128
KRAS INHIBITORS
2y 7m to grant Granted Nov 17, 2026
Patent 12790333
PIPERIDINYL-METHYL-PURINE AMINE D-TARTARIC ACID SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS
3y 5m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
97%
With Interview (+23.4%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1055 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month